NCT07544654

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-06-15Est. Completion: 2029-12-13

Enrollment target: 390 participants

Locations

Mayo Clinic, Scottsdale, Arizona, United States
City of Hope-Duarte-56419, Duarte, California, United States
Stanford Cancer Center, Palo Alto, California, United States
University of California San Francisco, San Francisco, California, United States
University of California Los Angeles, Santa Monica, California, United States
Mayo Clinic - Florida, Jacksonville, Florida, United States
Emory University, Atlanta, Georgia, United States
The Skip Viragh Outpatient Cancer Research Building, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Rochester, Minnesota, United States
Washington University School of Medicine, St Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
University of Tennessee, Knoxville, Tennessee, United States

Extensive-Stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaRecurrent or RefractorySolid Tumors

Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (E…

Bethesda, United StatesEst. completion Jan 30, 2030

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.